Determinants of specificity of MDM2 for the activation domains of p53 and p65: Proline27 disrupts the MDM2-binding motif of p53

Biochemistry

Volumn 45, Issue 39, 2006, Pages 11945-11957

  Zondlo, Susan Carr ^a   Lee, Aaron E ^a   Zondlo, Neal J ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; BINDING ENERGY; HYDROPHOBICITY; NUCLEAR MAGNETIC RESONANCE; POLYPEPTIDES; PROTEINS; SYNTHESIS (CHEMICAL);

ACTIVATION DOMAINS (AD); CHIMERIC PEPTIDES; HYDROPHOBIC SHORT LINEAR MOTIFS; LIGANDS;

MOLECULAR BIOLOGY;

PROLINE; PROTEIN MDM2; PROTEIN P53; SYNAPTOTAGMIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHIMERA; CIRCULAR DICHROISM; DISSOCIATION CONSTANT; ENZYME SPECIFICITY; GENE DISRUPTION; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR MODEL; MOLECULAR RECOGNITION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN SYNTHESIS; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; ANIMALS; CARRIER PROTEINS; HUMANS; NEOPLASM PROTEINS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; TATA-BINDING PROTEIN ASSOCIATED FACTORS; THERMODYNAMICS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR TFIID; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749378169     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi060309g     Document Type: Article

References (114)

1. Ptashne, M., and Gann, A. (1997) Transcriptional activation by recruitment, Nature 386, 569-577.
2. Wu, Y., Reece, R. J., and Ptashne, M. (1996) Quantitation of putative activator-target affinities predicts transcriptional activating potentials, EMBO J. 15, 3951-3963.
3. Melcher, K. (2000) The strength of acidic activation domains correlates with their affinity for both transcriptional and non-transcriptional proteins, J. Mol. Biol. 301, 1097-1112.
4. Han, Y., and Kodadek, T. (2000) Peptides selected to bind the Ga180 repressor are potent transcriptional activation domains in yeast, J. Biol. Chem. 275, 14979-14984.
5. Wu, Z. Q., Belanger, G., Brennan, B. B., Lum, J. K., Minter, A. R., Rowe, S. P., Plachetka, A., Majmudar, C. Y., and Mapp, A. K. (2003) Targeting the transcriptional machinery with unique artificial transcriptional activators, J. Am. Chem. Soc. 125, 12390-12391.
6. Gaston, K., and Jayaraman, P. S. (2003) Transcriptional repression in eukaryotes: Repressors and repression mechanisms, Cell. Mol. Life Sci. 60, 721-741.
7. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gvuris, J., Kinzler, K. W., and Vogelstein, B. (1993) Oncoprotein MDM2 conceals the activation domain of tumor suppressor-p53, Nature 362, 857-860.
8. Momand, J., Wu, H.-H., and Dasgupta, G. (2000) MDM2-Master regulator of the p53 tumor suppressor protein, Gene 242, 15-29.
9. Moll, U. M., and Petrenko, O. (2003) The MDM2-p53 interaction, Mol. Cancer Res. 1, 1001-1008.
10. Majmudar, C. Y., and Mapp, A. K. (2005) Chemical approaches to transcriptional regulation, Curr. Opin. Chem. Biol. 9, 467-474.
11. Bargonetti, J., and Manfredi, J. J. (2002) Multiple roles of the tumor suppressor p53, Curr. Opin. Oncol. 14, 86-91.
12. Harris, S. L., and Levine, A. J. (2005) The p53 pathway: Positive and negative feedback loops, Oncogene 24, 2899-2908.
13. Chene, P. (2003) Inhibiting the p53-MDM2 interaction: An important target for cancer therapy, Nat. Rev. Cancer 3, 102-109.
14. Chene, P. (2004) Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface, Mol. Cancer Res. 2, 20-28.
15. Fischer, P. M. (2006) Peptide, peptidomimetic, and small-molecule antagonists of the p53-hDM2 protein-protein interaction, Int. J. Pept. Res. Ther. 12, 3-19.
16. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992) The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation, Cell 69, 1237-1245.
17. II31 protein is a transcriptional coactivator of the p53 protein, Proc. Natl. Acad. Sci. U.S.A. 92, 5154-5158.
18. Lee, T. I., and Young, R. A. (1998) Regulation of gene expression by TBP-associated proteins, Genes Dev. 12, 1398-1408.
19. Uesugi, M., and Verdine, G. L. (1999) The α-helical FXXΦΦ motif in p53: TAF interaction and discrimination by MDM2, Proc. Natl. Acad. Sci. U.S.A. 96, 14801-14806.
20. Kussie, P. H., Gorina, S., Marechal, B. E., Moreau, J., Levine, A. J., and Pavletich, N. P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain, Science 274, 948-952.
21. Uesugi, M., Nyanguile, O., Lu, H., Levine, A. J., and Verdine, G. L. (1997) Induced α helix in the VP16 activation domain upon binding to a human TAF, Science 277, 1310-1313.
22. II31-binding motifs hidden in activation domains, J. Biol. Chem. 275, 15912-15916.
23. II31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21, Oncogene 21, 7100-7113.
24. Botuyan, M. V. E., Momand, J., and Chen, Y. (1997) Solution conformation of an essential region of the p53 transactivation domain, Folding Des. 2, 331-342.
25. Lin, J. Y., Chen, J. D., Elenbaas, B., and Levine, A. J. (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to MDM-2 and the adenovirus-5 E1b 55-kD protein, Genes Dev. 8, 1235-1246.
26. Picksley, S. M., Vojtesek, B., Sparks, A., and Lane, D. P. (1994) Immunochemical analysis of the interaction of p53 with MDM2-Fine mapping of the MDM2 binding site on p53 using synthetic peptides, Oncogene 9, 2523-2529.
27. Bottger, V., Bottger, A., Howard, S. F., Picksley, S. M., Chene, P., GarciaEcheverria, C., Hochkeppel, H. K., and Lane, D. P. (1996) Identification of novel MDM2 binding peptides by phage display, Oncogene 13, 2141-2147.
28. Bottger, A., Bottger, V., GarciaEcheverria, C., Chene, P., Hochkeppel, H. K., Sampson, W., Ang, K., Howard, S. F., Picksley, S. M., and Lane, D. P. (1997) Molecular characterization of the hDM2-p53 interaction, J. Mol. Biol. 269, 744-756.
29. Lai, Z. H., Auger, K. R., Manubay, C. M., and Copeland, R. A. (2000) Thermodynamics of p53 binding to hDM2(1-126): Effects of phosphorylation and p53 peptide length, Arch. Biochem. Biophys. 381, 278-284.
30. Schon, O., Friedler, A., Bycroft, M., Freund, S. M. V., and Fersht, A. R. (2002) Molecular mechanism of the interaction between MDM2 and p53, J. Mol. Biol. 323, 491-501.
31. Giniger, E., and Ptashne, M. (1987) Transcription in yeast activated by a putative amphipathic α-helix linked to a DNA-binding unit, Nature 330, 670-672.
32. Schmitz, M. L., Silva, M. A. D., Altmann, H., Czisch, M., Holak, T. A., and Baeuerle, P. A. (1994) Structural and functional analysis of the NF-K-B p65 C-terminus-An acidic and modular transactivation domain with the potential to adopt an α-helical conformation, J. Biol. Chem. 269, 25613-25620.
33. Buss, H., Dorrie, A., Schmitz, M. L., Hoffmann, E., Resch, K., and Kracht, M. (2004) Constitutive and interleukin-1-inducible phosphorylation of p65 NF-KB at serine 536 is mediated by multiple protein kinases including IKB kinase (IKK)-α, IKKβ, IKKε, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription, J. Biol. Chem. 279, 55633-55643.
34. Schmitz, M. L., Mattioli, I., Buss, H., and Kracht, M. (2004) NF-KB: A multifaceted transcription factor regulated at several levels, ChemBioChem 5, 1348-1358.
35. Zhao, L., and Chmielewski, J. (2005) Inhibiting protein-protein interactions using designed molecules, Curr. Opin. Struct. Biol. 15, 31-34.
36. Bond, G. L., Hu, W. W., and Levine, A. J. (2005) MDM2 is a central node in the p53 pathway: 12 years and counting, Curr. Cancer Drug Targets 5, 3-8.
37. Arkin, M. (2005) Protein-protein interactions and cancer: Small molecules going in for the kill, Curr. Opin. Chem. Biol. 9, 317-324.
38. Darimont, B. D., Wagner, R. L., Apriletti, J. W., Stallcup, M. R., Kushner, P. J., Baxter, J. D., Fletterick, R. J., and Yamamoto, K. R. (1998) Structure and specificity of nuclear receptor-coactivator interactions, Genes Dev. 12, 3343-3356.
39. McInerney, E. M., Rose, D. W., Flynn, S. E., Westin, S., Mullen, T.-M., Krones, A., Inostroza, J., Torchia, J., Nolte, R. T., Assa-Munt, N., Milburn, M. V., Glass, C. K., and Rosenfeld, M. G. (1998) Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation, Genes Dev. 12, 3357-3368.
40. He, B., and Wilson, E. M. (2003) Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs, Mol. Cell. Biol. 23, 2135-2150.
41. Hermann, S., Berndt, K. D., and Wright, A. P. (2001) How transcriptional activators bind target proteins, J. Biol. Chem. 276, 40127-40132.
42. Ferreira, M. E., Hermann, S., Prochasson, P., Workman, J. L., Berndt, K. D., and Wright, A. P. H. (2005) Mechanism of transcription factor recruitment by acidic activators, J. Biol. Chem. 280, 21779-21784.
43. Aurora, R., and Rose, G. D. (1998) Helix capping, Protein Sci. 7, 21-38.
44. Massova, I., and Kollman, P. A. (1999) Computational alanine scanning to probe protein-protein interactions: A novel approach to evaluate binding free energies, J. Am. Chem. Soc. 121, 8133-8143.
45. Iqbalsyah, T. M., and Doig, A. J. (2005) Pairwise coupling in an Arg-Phe-Met triplet stabilizes α-helical peptide via shared rotamer preferences, J. Am. Chem. Soc. 127, 5002-5003.
46. Garcia-Echeverria, C., Chene, P., Blommers, M. J. J., and Furet, P. (2000) Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53, J. Med. Chem. 43, 3205-3208.
47. Zhang, R. M., Mayhood, T., Lipari, P., Wang, Y. L., Durkin, J., Syto, R., Gesell, J., McNemar, C., and Windsor, W. (2004) Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction, Anal. Biochem. 331, 138-146.
48. Bottger, A., Bottger, V., Sparks, A., Liu, W. L., Howard, S. F., and Lane, D. P. (1997) Design of a synthetic MDM2-binding mini protein that activates the p53 response in vivo, Curr. Biol. 7, 860-869.
49. Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Muhlhahn, P., Schumacher, R., Hesse, F., Kaluza, B., Voelter, W., Engh, R. A., and Holak, T. A. (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53, Biochemistry 40, 336-344.
50. Zhao, J. H., Wang, M. J., Chen, J., Luo, A. P., Wang, X. Q., Wu, M., Yin, D. L., and Liu, Z. H. (2002) The initial evaluation of non-peptidic small-molecule hDM2 inhibitors based on p53-hDM2 complex structure, Cancer Lett. 183, 69-77.
51. Banerjee, R., Basu, G., Chene, P., and Roy, S. (2002) Aib-based peptide backbone as scaffolds for helical peptide mimics, J. Pept. Res. 60, 88-94.
52. Alluri, P. G., Reddy, M. M., Bachhawat-Sikder, K., Olivos, H. J., and Kodadek, T. (2003) Isolation of protein ligands from large peptoid libraries, J. Am. Chem. Soc. 125, 13995-14004.
53. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, Science 303, 844-848.
54. Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Vrijbloed, J. W., Obrecht, D., and Robinson, J. A. (2004) Using a β-hairpin to mimic an α-helix: Cyclic peptidomimetic inhibitors of the p53-hDM2 protein-protein interaction, Angew. Chem., Int. Ed. 43, 2109-2112.
55. Kritzer, J. A., Lear, J. D., Hodsdon, M. E., and Schepartz, A. (2004) Helical β-peptide inhibitors of the p53-hDM2 interaction, J. Am. Chem. Soc. 126, 9468-9469.
56. Sakurai, K., Chung, H. S., and Kahne, D. (2004) Use of a retroinverso p53 peptide as an inhibitor of MDM2, J. Am. Chem. Soc. 126, 16288-16289.
57. Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y. S., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., Parrish, D. A., Deschamps, J. R., and Wang, S. M. (2005) Structure-based design of potent non-peptide MDM2 inhibitors, J. Am. Chem. Soc. 127, 10130-10131.
58. Grasberger, B. L., Lu, T. B., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., Maguire, D., Lattanze, J., Franks, C. F., Zhao, S. Y., Ramachandren, K., Bylebyl, G. R., Zhang, M., Manthey, C. L., Petrella, E. C., Pantoliano, M. W., Deckman, I. C., Spurlino, J. C., Maroney, A. C., Tomczuk, B. E., Molloy, C. J., and Bone, R. F. (2005) Discovery and cocrystal structure of benzodiazepinedione hDM2 antagonists that activate p53 in cells, J. Med. Chem. 48, 909-912.
59. Yin, H., Lee, G. I., Park, H. S., Payne, G. A., Rodriguez, J. M., Sebti, S. M., and Hamilton, A. D. (2005) Terphenyl-based helical mimetics that disrupt the p53/hDM2 interaction, Angew. Chem., Int. Ed. 44, 2704-2707.
60. Kritzer, J. A., Hodsdon, M. E., and Schepartz, A. (2005) Solution structure of a β-peptide ligand for hDM2, J. Am. Chem. Soc. 127, 4118-4119.
61. Kritzer, J. A., Zutshi, R., Cheah, M., Ran, F. A., Webman, R., Wongjirad, T. M., and Schepartz, A. (2006) Miniature protein inhibitors of the p53-hDM2 interaction, ChemBioChem 7, 29-31.
62. Hara, T., Durell, S. R., Myers, M. C., and Appella, D. H. (2006) Probing the structural requirements of peptoids that inhibit hDM2-p53 interactions, J. Am. Chem. Soc. 128, 1995-2004.
63. Cammers-Goodwin, A., Allen, T. J., Oslick, S. L., McClure, K. F., Lee, J. H., and Kemp, D. S. (1996) Mechanism of stabilization of helical conformations of polypeptides by water containing trifluoroethanol, J. Am. Chem. Soc. 118, 3082-3090.
64. Lee, H., Mok, K. H., Muhandiram, R., Park, K. H., Suk, J. E., Kim, D. H., Chang, J., Sung, Y. C., Choi, K. Y., and Han, K. H. (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53, J. Biol. Chem. 275, 29426-29432.
65. Rosal, R., Pincus, M. R., Brandt-Rauf, P. W., Fine, R. L., Michl, J., and Wang, H. (2004) NMR solution structure of a peptide from the MDM-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells, Biochemistry 43, 1854-1861.
66. Vise, P. D., Baral, B., Latos, A. J., and Daughdrill, G. W. (2005) NMR chemical shift and relaxation measurements provide evidence for the coupled folding and binding of the p53 transactivation domain, Nucleic Acids Res. 33, 2061-2077.
67. 13C nuclear magnetic resonance chemical shifts, J. Am. Chem. Soc. 113, 5490-5492.
68. Wishart, D. S., Sykes, B. D., and Richards, F. M. (1991) Relationship between nuclear magnetic resonance chemical shift and protein secondary structure, J. Mol. Biol. 222, 311-333.
69. Wishart, D. S., Sykes, B. D., and Richards, F. M. (1992) The chemical shift index: A fast and simple method for the assignment of protein secondary structure through NMR spectroscopy, Biochemistry 31, 1647-1651.
70. Wishart, D. S., and Sykes, B. D. (1994) The C-13 chemical shift index-A simple method for the identification of protein secondary structure using C-13 chemical-shift data, J. Biomol. NMR 4, 171-180.
71. Presta, L. G., and Rose, G. D. (1988) Helix signals in proteins, Science 240, 1632-1641.
72. Wu, W.-J., and Raleigh, D. P. (1998) Local control of peptide conformation: Stabilization of cis proline peptide bonds by aromatic proline interactions, Biopolymers 45, 381-394.
73. Thomas, K. M., Naduthambi, D., and Zondlo, N. J. (2006) Electronic control of amide cis-trans isomerism via the aromatic-prolyl interaction, J. Am. Chem. Soc. 128, 2216-2217.
74. Espinoza-Fonseca, L. M., and Trujillo-Ferrara, J. G. (2006) Transient stability of the helical pattern of region F19-L22 of the N-terminal domain of p53: A molecular dynamics simulation study, Biochem. Biophys. Res. Commun. 343, 110-116.
75. Walker, K. K., and Levine, A. J. (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression, Proc. Natl. Acad. Sci. U.S.A. 93, 15335-15340.
76. Ruaro, E. M., Collavin, L., DelSal, G., Haffner, R., Oren, M., Levine, A. J., and Schneider, C. (1997) A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1, Proc. Natl. Acad. Sci. U.S.A. 94, 4675-4680.
77. Venot, C., Maratrat, M., Dureuil, C., Conseiller, E., Bracco, L., and Debussche, L. (1998) The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression, EMBO J. 17, 4668-4679.
78. Berger, M., Sionov, R. V., Levine, A. J., and Haupt, Y. (2001) A role for the polyproline domain of p53 in its regulation by MDM2, J. Biol. Chem. 276, 3785-3790.
79. Zhu, J. H., Zhou, W. J., Jiang, J. Y., and Chen, X. B. (1998) Identification of a novel p53 functional domain that is necessary for mediating apoptosis, J. Biol. Chem. 273, 13030-13036.
80. Zhu, J. H., Jiang, J. Y., Zhou, W. J., Zhu, K. C., and Chen, X. B. (1999) Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity, Oncogene 18, 2149-2155.
81. Zhu, J., Zhang, S., Jiang, J., and Chen, X. (2000) Definition of the p53 functional domains necessary for inducing apoptosis, J. Biol. Chem. 2000, 39927-39934.
82. Jiang, M., Axe, T., Holgate, R., Rubbi, C. P., Okorokov, A. L., Mee, T., and Milner, J. (2001) p53 binds the nuclear matrix in normal cells: Binding involves the proline-rich domain of p53 and increases following genotoxic stress, Oncogene 20, 5449-5458.
83. Baptiste, N., Friedlander, P., Chen, X. B., and Prives, C. (2002) The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells, Oncogene 21, 9-21.
84. Dornan, D., Shimizu, H., Burch, L., Smith, A. J., and Hupp, T. R. (2003) The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53, Mol. Cell. Biol. 23, 8846-8861.
85. Liu, G., Xia, T., and Chen, X. (2003) The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein, J. Biol. Chem. 278, 17557-17565.
86. Wright, P. E., and Dyson, H. J. (1999) Intrinsically unstructured proteins: Re-assessing the protein structure-function paradigm, J. Mol. Biol. 293, 321-331.
87. Dunker, A. K., Brown, C. J., Lawson, J. D., Iakoucheva, L. M., and Obradovic, Z. (2002) Intrinsic disorder and protein function, Biochemistry 41, 6573-6582.
88. Iakoucheva, L. M., Brown, C. J., Lawson, J. D., Obradovic, Z., and Dunker, A. K. (2002) Intrinsic disorder in cell-signaling and cancer-associated proteins, J. Mol. Biol. 323, 573-584.
89. Oldfield, C. J., Cheng, Y. G., Cortese, M. S., Romero, P., Uversky, V. N., and Dunker, A. K. (2005) Coupled folding and binding with α-helix-forming molecular recognition elements, Biochemistry 44, 12454-12470.
90. Moarefi, I., LaFevreBernt, M., Sicheri, F., Huse, M., Lee, C. H., Kuriyan, J., and Miller, W. T. (1997) Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement, Nature 385, 650-653.
91. Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, V., Clarkson, B., Superti-Furga, G., and Kuriyan, J. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase, Cell 112, 859-871.
92. Lu, Z., Rowe, S. P., Brennan, B. B., Davis, S. E., Metzler, R. E., Nau, J. J., Majmudar, C. Y., Mapp, A. K., and Ansari, A. Z. (2005) Unraveling the mechanism of a potent transcriptional activator, J. Biol. Chem. 280, 29689-29698.
93. IIs directing synergistic activation of transcription, Science 270, 1783-1788.
94. Farmer, G., Colgan, J., Nakatani, Y., Manley, J. L., and Prives, C. (1996) Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo, Mol. Cell. Biol. 16, 4295-4304.
95. II31, J. Biol. Chem. 276, 13852-13857.
96. Ansari, A. Z., Mapp, A. K., Nguyen, D. H., Dervan, P. B., and Ptashne, M. (2001) Towards a minimal motif for artificial transcriptional activators, Chem. Biol. 8, 583-592.
97. Zondlo, N. J., and Schepartz, A. (1999) Highly specific DNA recognition by a designed miniature protein, J. Am. Chem. Soc. 121, 6938-6939.
98. Regier, J. L., Shen, F., and Triezenberg, S. J. (1993) Pattern of aromatic and hydrophobia amino acids critical for one of 2 subdomains of the VP16 transcriptional activator, Proc. Natl. Acad. Sci. U.S.A. 90, 883-887.
99. Cress, W. D., and Triezenberg, S. J. (1991) Critical structural elements of the VP16 transcriptional activation domain, Science 251, 87-90.
100. Arora, P. S., Ansari, A. Z., Best, T. P., Ptashne, M., and Dervan, P. B. (2002) Design of artificial transcriptional activators with rigid poly-L-proline linkers, J. Am. Chem. Soc. 124, 13067-13071.
101. Minter, A. R., Brennan, B. B., and Mapp, A. K. (2004) A small molecule transcriptional activation domain, J. Am. Chem. Soc. 126, 10504-10505.
102. Buhrlage, S. J., Brennan, B. B., Minter, A. R., and Mapp, A. K. (2005) Stereochemical promiscuity in artificial transcriptional activators, J. Am. Chem. Soc. 127, 12456-12457.
103. Majmudar, C. Y., Lum, J. K., Prasov, L., and Mapp, A. K. (2005) Functional specificity of artificial transcriptional activators, Chem. Biol. 12, 313-321.
104. Lum, J. K., and Mapp, A. K. (2005) Artificial transcriptional activation domains, ChemBioChem 6, 1311-1315.
105. Taatjes, D. J., Marr, M. T., and Tjian, R. (2004) Opinion-Regulatory diversity among metazoan co-activator complexes, Nat. Rev. Mol. Cell. Biol. 5, 403-410.
106. Schon, O., Friedler, A., Freund, S., and Fersht, A. R. (2004) Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes, J. Mol. Biol. 336, 197-202.
107. Liu, J., Perumal, N. B., Oldfield, C. J., Su, E. W., Uversky, V. N., and Dunker, A. K. (2006) Intrinsic disorder in transcription factors, Biochemistry 45, 6873-6888.
108. Chi, S. W., Lee, S. H., Kim, D. H., Ahn, M. J., Kim, J. S., Woo, J. Y., Torizawa, T., Kainosho, M., and Han, K. H. (2005) Structural details on MDM2-p53 interaction, J. Biol. Chem. 280, 38795-38802.
109. Frangioni, J. V., LaRiccia, L. M., Cantley, L. C., and Montminy, M. R. (2000) Minimal activators that bind to the KIX domain of p300/CBP identified by phage display screening, Nat. Biotechnol. 18, 1080-1085.
110. Parker, D., Rivera, M., Zor, T., Henrion-Caude, A., Radhakrishnan, I., Kumar, A., Shapiro, L. H., Wright, P. E., Montminy, M., and Brindle, P. K. (1999) Role of secondary structure in discrimination between constitutive and inducible activators, Mol. Cell. Biol. 19, 5601-5607.
111. Shimogawa, H., Kwon, Y., Mao, Q., Kawazoe, Y., Choi, Y., Asada, S., Kigoshi, H., and Uesugi, M. (2004) A wrench-shaped synthetic molecule that modulates a transcription factor-coactivator interaction, J. Am. Chem. Soc. 126, 3461-3471.
112. Best, J. L., Amezcua, C. A., Mayr, B., Flechner, L., Murawsky, C. M., Emerson, B., Zor, T., Gardner, K. H., and Montminy, M. (2004) Identification of small-molecule antagonists that inhibit an activator-coactivator interaction, Proc. Natl. Acad. Sci. U.S.A. 101, 17622-17627.
113. Volkman, H. M., Rutledge, S. E., and Schepartz, A. (2005) Binding mode and transcriptional activation potential of high affinity ligands for the CBPKIX domain, J. Am. Chem. Soc. 127, 4649-4658.
114. Liu, B., Alluri, P. G., Yu, P., and Kodadek, T. (2005) A potent transactivation domain mimic with activity in living cells, J. Am. Chem. Soc. 127, 8254-8255.